Location: New York, NY
CIK: 0001766721 · Show all filings
Period: Q2 2026 (← Previous)
Filing Date: Aug 13, 2026
Total Value: $472M (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| VTVT | VTV THERAPEUTICS INC | 50,000 | $1.883M | 0.4% | $37.65 | — | CL A NEW | 918385204 |
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| BBIO | BRIDGEBIO PHARMA INC | 4,589,611 (-9.8%) | $342M (-9.6%) | 72.5% | $40.43 | — | COM | 10806X102 |
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CMPS | COMPASS PATHWAYS PLC | 1,432,336 | $20.27M | 4.3% | $6.35 | — | SPONSORED ADS | 20451W101 |
| GLUE | MONTE ROSA THERAPEUTICS INC | 1,555,664 | $37.65M | 8.0% | $20.38 | — | COM | 61225M102 |
| BCAX | BICARA THERAPEUTICS INC | 568,919 | $16.89M | 3.6% | $25.50 | — | COM | 055477103 |
| URGN | UROGEN PHARMA LTD | 108,000 | $3.974M | 0.8% | $21.69 | — | COM | M96088105 |
| SNDX | SYNDAX PHARMACEUTICALS INC | 1,316,806 | $28.79M | 6.1% | $10.41 | — | COM | 87164F105 |
| BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | 1,018,018 | $7.757M | 1.6% | $10.41 | — | COM NEW | 107924102 |
| ACRS | ACLARIS THERAPEUTICS INC | 434,455 | $2.298M | 0.5% | $10.31 | — | COM | 00461U105 |
| SRRK | SCHOLAR ROCK HLDG CORP | 77,031 | $4.237M | 0.9% | $34.98 | — | COM | 80706P103 |
| EPRX | EUPRAXIA PHARMACEUTICALS INC | 325,000 | $2.148M | 0.5% | $8.37 | — | COM | 29842P105 |
| BMEA | BIOMEA FUSION INC | 2,048,757 | $3.012M | 0.6% | $8.06 | — | COM | 09077A106 |
| MRKR | MARKER THERAPEUTICS INC | 325,370 | $478K | 0.1% | $1.80 | — | COM NEW | 57055L206 |
| OKUR | ONKURE THERAPEUTICS INC | 88,607 | $404K | 0.1% | $15.14 | — | COM CL A | 68277Q105 |